10-K: Aptose Biosciences Inc. Announces 2024 Financial Results and Provides Corporate Update

Sentiment:

Annual Results 28 March 2025 10:46 AM

Aptose Biosciences Inc. files its 2024 10-K, highlighting clinical advancements in tuspetinib and luxeptinib programs while addressing financial challenges and Nasdaq compliance.

Capital raiseThe company needs to raise additional capital to fund its operations and may be unable to do so on acceptable terms.The company plans to raise additional funds through equity financing or other financing activities.Management continues considering other options for raising capital including debt, equity, through collaborations or reorganization to reduce operational expenses.

Worse than expectedThe company reported a net loss of $25.4 million for the year ended December 31, 2024, and has a history of operating losses.The company's cash, cash equivalents, and restricted cash decreased from $9.3 million to $6.7 million.The company has negative shareholders' equity of $4.5 million as of December 31, 2024.The company has sufficient liquidity to support the Company's operations until April 2025.

Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly hematologic cancers.
The company's lead asset, tuspetinib, is being developed for frontline combination therapy in newly diagnosed AML patients.
Tuspetinib has shown promising safety and efficacy data in relapsed or refractory AML patients, leading to its advancement into a triplet combination therapy trial for newly diagnosed AML.
Aptose is conducting a Phase 1/2 clinical trial with tuspetinib in combination with venetoclax and azacitidine for newly diagnosed AML patients.
Luxeptinib, Aptose's second agent, is an oral kinase inhibitor with potential in myeloid and lymphoid hematologic malignancies, but further development is paused due to funding prioritization.
Aptose is exploring alternative development paths and collaborations for luxeptinib, including a potential investigator-sponsored trial in combination with venetoclax for a molecularly defined subgroup of CLL patients.
The company faces financial challenges, including a history of operating losses and the need to raise additional capital to fund its operations.
Aptose received deficiency letters from Nasdaq regarding minimum bid price and stockholders' equity requirements and has taken steps to regain compliance.
The company is subject to various risks and uncertainties, including the ability to raise capital, the success of clinical trials, and competition in the biotechnology and pharmaceutical industries.
As of the filing date, the company has sufficient liquidity to support the Company's operations until April 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive clinical updates, the financial situation and Nasdaq compliance issues weigh negatively.

Positives

Tuspetinib has demonstrated a favorable safety profile and promising efficacy in AML patients.
The NCI is collaborating with Aptose on the clinical development of tuspetinib.
Luxeptinib's G3 formulation has shown improved absorption and tolerability.
Aptose has taken steps to regain compliance with Nasdaq listing requirements.
Tuspetinib has received Orphan Drug Designation from the FDA.

Negatives

Aptose has a history of operating losses and expects to incur net losses in the future.
The company needs to raise additional capital to fund its operations and may be unable to do so on acceptable terms.
Aptose received deficiency letters from Nasdaq regarding minimum bid price and stockholders' equity requirements.
The company is an early-stage development company with no revenues from product sales.
The company has decided to pause funding the development of luxeptinib.

Risks

The company's ability to continue as a going concern is subject to substantial doubt.
Clinical trials are long, expensive, and uncertain processes, and regulatory approval may not be obtained.
The company relies on contract manufacturers, and quality, cost, or delivery issues could harm its business.
The marketplace may not accept the company's products or product candidates due to intense competition and technological change.
The company may be unable to obtain patents to protect its technologies.
The company is subject to U.S. and Canadian healthcare laws and regulations, which could expose it to criminal sanctions and civil penalties.
The company's share price has been and is likely to continue to be volatile.

Future Outlook

Aptose expects research and development expenses to be lower in 2025 than in 2024, subject to successful new financing activities. Costs will increase as tuspetinib advances into more extensive clinical trials unless the program is partnered.

Management Comments

Based on the safety and efficacy profile of tuspetinib, we believe that tuspetinib as part of the TUS+VEN+HMA triplet, if approved, could establish a new standard of care therapy for newly diagnosed patients with mutated or unmutated FLT3 and in patients with other adverse genetic abnormalities.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and intense competition. There are numerous companies in these industries that are focusing their efforts on activities similar to ours.

Comparison to Industry Standards

For tuspetinib and luxeptinib in AML, examples of companies that have developed or are pursuing different therapies include AbbVie and Roche (VENCLEXTA), Agios/Servier (TIBSOVO), Arog (crenolanib), Astellas (XOSPATA), Celgene/BMS (IDHIFA), Curis (emavusertib), Daiichi Sankyo (quizartinib), Jazz (VYXEOS), Kronos Bio (lanraplenib), Kura (KO-539), Novartis (RYDAPT), Pfizer (MYLOTARG), Rigel (REZLIDHA), and Syndax (revumenib, SNDX-5613), among others.
For luxeptinib in B cell malignancies, examples of companies that have developed or are pursuing different approaches to BTK inhibition, both for the wild type and C481S-mutant forms, include AbbVie (IMBRUVICA), AstraZeneca (CALQUENCE), Beigene Co., Ltd. (Zanubrutinib), Eli Lilly (pirtobrutinib), and Merck (nemtabrutinib), among others.

Related Party Transactions

Hanmi Pharmaceutical Co. Ltd. is a related party due to the Tuspetinib Licensing Agreement and the Hanmi Loan Agreement.
The Company has maximum obligations for clinical development and global regulatory milestones totaling $64.5 million for the first potential clinical indication of tuspetinib, $34 million for the second indication, and $29 million for the third indication.
The Company has maximum obligations for tiered global sales-based milestones totaling $280 million.
The Company also has an obligation for tiered royalty payments on global sales of commercialized product.
The loan is repayable in full on January 31, 2027, with an initial interest period ended on September 30, 2024 and subsequent interest payments due at the end of each three-month period thereafter.
Aptose may repay all or any portion of the outstanding principal at any time without penalty, provided that any accrued and unpaid interest on the principal amount being repaid is also settled.
The accrued interest on the unpaid principal loan is payable at the periods specified on the Hanmi Loan Agreement at a rate of 6% per annum.
On September 2, 2024, and in connection with the Hanmi Loan Agreement, Aptose and Hanmi executed a letter of understanding, which outlines the steps associated with the negotiation of a co-development collaboration agreement for the advancement of tuspetinib (the Future Collaboration Agreement).
Under the terms of the Future Collaboration Agreement, upon execution, the loan principal and any accrued and unpaid interest under the Hanmi Loan Agreement will automatically convert to Hanmi's prepayment of future milestone obligations under the Future Collaboration Agreement.
Upon conversion, the Hanmi Loan Agreement, consisting of the $10 million loan principal with any accrued and unpaid interest, would be deemed fully paid and satisfied.
Hanmi has a security interest over all inventory of drug substances and drug products related to the Tuspetinib License Agreement.
At December 31, 2024 Hanmi held 99,647 Common Shares and 77,972 warrants to purchase Common Shares at an exchange price of $51.30 per Common Shares of Aptose.

Stakeholder Impact

Shareholders face potential dilution from future equity financings and volatility in the share price.
Employees may be affected by potential cost-cutting measures or changes in development programs.
Patients may benefit from the continued development of tuspetinib and luxeptinib, but clinical trials are subject to delays and uncertainties.
Suppliers and creditors may be impacted by the company's financial challenges and ability to meet its obligations.

Next Steps

Continue Phase 1/2 clinical trial of tuspetinib in combination with venetoclax and azacitidine for newly diagnosed AML patients.
Explore alternative development paths and collaborations for luxeptinib.
Demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) requiring the Company to have a minimum of $2.5 million in shareholders equity (the Equity Rule) to continue its listing on the Nasdaq Stock Market.

Key Dates

Date	Description
1986	Aptose was founded.
May 7, 2018	Aptose exercised an option to purchase an exclusive license to luxeptinib.
June 14, 2018	Aptose entered into a license agreement with CG for rights to CG-806 in China.
January 1, 2020	Dr. Rafael Bejar joined Aptose as Senior Vice President and Chief Medical Officer.
November 4, 2021	Aptose entered into the Tuspetinib Licensing Agreement with Hanmi.
June 27, 2022	Fletcher Payne joined Aptose as Senior Vice President, Chief Business Officer, Chief Financial Officer (CFO), and Corporate Secretary.
December 9, 2023	Aptose featured tuspetinib in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
January 30, 2024	Aptose completed a public offering of Common Shares.
January 31, 2024	Aptose completed a private placement with Hanmi.
March 26, 2024	Aptose announced that more than 170 patients to date received TUS alone or in combination with the BCL-2 inhibitor venetoclax (VEN) during the Phase 1/2 clinical program in the very ill relapsed or refractory (R/R) AML patient population.
April 2, 2024	Aptose received a letter from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) because the stockholders equity of the Company as of December 31, 2023, as reported in the Companys Annual Report on Form 10-K filed with the SEC on March 26, 2024, was below the minimum requirement of $2,500,000.
May 16, 2024	The myeloMATCH precision medicine trials (NCT05564390), funded by the NCI, were officially launched.
June 3, 2024	Aptose completed the Registered Direct Offering for the purchase and sale of 60,000 Common Shares at a purchase price of $34.50 per Common Share and 68,500 pre-funded warrants.
June 14, 2024	Aptose presented tuspetinib (TUS) clinical findings as a clinical poster presentation and preclinical findings as a e-poster at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.
July 16, 2024	The Company received a deficiency letter from the Nasdaq, notifying the Company that, for the prior thirty consecutive business days, the closing bid price for the Companys Common Shares was below the minimum $1.00 per Common Share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).
August 27, 2024	The Company and Hanmi Pharmaceutical Co. Ltd. (Hanmi) entered into a loan agreement, pursuant to which Hanmi agreed to loan $10 million to Aptose.
September 5, 2024	The Company held a Special Meeting of Shareholders pursuant to which, shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying certain warrants in an amount equal to or in excess of 20% of our Common Shares outstanding immediately prior the issuance of such warrants pursuant to the June 2024 Registered Direct Offering.
September 11, 2024	The Company issued 68,500 Common Shares upon the exercise of 68,500 Pre-Funded Warrants for a cash proceeds of $2 thousand at an exercise price of $0.03.
November 25, 2024	The Company completed a reasonable best efforts public offering (the November 2024 Public Offering) with participation from our CEO and existing and new healthcare focused investors for the purchase and sale of 1,333,333 Common Shares at a price of $6.00 per share and warrants to purchase up to 666,599 Common Shares.
December 3, 2024	The Company announced that the National Cancer Institute (NCI), part of the National Institutes of Health, and Aptose Biosciences Inc. have entered into a Cooperative Research and Development Agreement (CRADA).
December 2024	Aptose attended the 66th Annual American Society of Hematology (ASH) Meeting and Exposition in San Diego, California, and presented a poster entitled Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML.
January 9, 2025	Aptose announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML.
January 12, 2025	Aptose announced promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptoses Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet).
January 14, 2025	The Company received an additional staff determination letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Companys common shares was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement).
January 20, 2025	Aptose announced that the Cohort Safety Review Committee (CSRC) monitoring Aptoses Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has unanimously approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
January 27, 2025	The Company held a Special Meeting of the shareholders of the Corporation (the Meeting). At the Meeting, shareholders voted in favor of an amendment to the Corporations Articles of Incorporation, as amended, to, at the discretion of the Companys board of directors (the Board), to effect a Reverse Stock Split, with the ratio within such range to be determined at the discretion of the Board.
February 3, 2025	On February 3, 2025, the Company and AGP entered into a sales agreement pursuant to which the Company may from time to time, sell Common Shares having an aggregate offering value of up to $1 million through AGP on Nasdaq (the 2025 ATM Facility).
February 7, 2025	On February 7, 2025, the Company and Keystone entered into the Purchase Agreement, which provides that subject to the terms and conditions set forth therein, the Company may sell to Keystone up to the greater of (i) $25 million of the Common Shares and (ii) the Exchange Cap (as defined below) (subject to certain exceptions provided in the Purchase Agreement) (the Total Commitment), from time to time during the two year term of the Purchase Agreement.
February 18, 2025	The Board approved a ratio of 1-for-30 reverse stock split.
February 26, 2025	Our Common Shares commenced trading on a post-Reverse Stock Split basis at market open.
March 14, 2025	Nasdaq confirmed that we had regained compliance with the Minimum Bid Price Requirement.
March 18, 2025	The Company entered into a debt conversion and interest payment agreement (Debt Conversion Agreement) with Hanmi pursuant to which the Company and Hanmi agreed to convert $1.5 million of Hanmis indebtedness under the Hanmi Loan Agreement into 409,063 Common Shares at $3.70 per share which was the average closing price of the Companys Common Shares on Nasdaq for the five trading days immediately prior to entering into the Debt Conversion Agreement.
March 28, 2025	As of March 28, 2025, the Company has not yet been able to regain compliance with the Nasdaq's minimum equity requirement of $2.5 million (the Stockholders Equity Requirement).

Keywords

tuspetinib, luxeptinib, AML, Aptose, clinical trials, oncology, biotechnology, hematology, kinase inhibitor, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.